These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31918322)

  • 1. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study.
    Liu KH; Zhang L; Chen JX; Lian CL; Wang J; He ZY; Wu SG
    Breast; 2020 Feb; 49():233-241. PubMed ID: 31918322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer.
    Chen XH; Zhang WW; Wang J; Sun JY; Li FY; He ZY; Wu SG
    Biomark Med; 2019 Feb; 13(2):83-93. PubMed ID: 30565472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.
    Zhou P; Zhang WW; Bao Y; Wang J; Lian CL; He ZY; Wu SG
    Breast; 2020 Dec; 54():319-327. PubMed ID: 33278648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
    Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
    Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
    Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
    Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases.
    Chen WR; Deng JP; Wang J; Sun JY; He ZY; Wu SG
    Cancer Res Treat; 2019 Oct; 51(4):1437-1448. PubMed ID: 30913871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis.
    Ding S; Wu J; Lin C; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2019 Feb; 19(1):e66-e73. PubMed ID: 30396812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic factors of early breast cancer].
    Almagro E; González CS; Espinosa E
    Med Clin (Barc); 2016 Feb; 146(4):167-71. PubMed ID: 25726309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30.
    Yang SP; Yao J; Zhou P; Lian CL; Wang J; Fang MX; Wu SG
    Future Oncol; 2021 Jun; 17(17):2183-2192. PubMed ID: 33605163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
    Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
    JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy.
    Park KU; Chen Y; Chitale D; Choi S; Ali H; Nathanson SD; Bensenhaver J; Proctor E; Petersen L; Loutfi R; Simonds A; Kuklinski M; Doyle T; Dabak V; Cole K; Davis M; Newman L
    Ann Surg Oncol; 2018 Jul; 25(7):1921-1927. PubMed ID: 29679201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
    Tong Y; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    Sci Rep; 2019 Sep; 9(1):13123. PubMed ID: 31511599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 21-Gene Recurrence Score Testing in HER2-positive Patients.
    Altman AM; Marmor S; Tuttle TM; Hui JYC
    Clin Breast Cancer; 2019 Apr; 19(2):126-130. PubMed ID: 30595493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
    Felts JL; Zhu J; Han B; Smith SJ; Truica CI
    Breast J; 2017 Nov; 23(6):677-686. PubMed ID: 28097781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx.
    Lee RM; Switchenko JM; Ho TB; Arciero CA; Bhave MA; Subhedar PD
    Ann Surg Oncol; 2019 Oct; 26(10):3152-3158. PubMed ID: 31342377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of 21-gene recurrence score results and ASTRO suitability criteria in breast cancer patients treated with intraoperative radiation therapy (IORT).
    Schwartzberg BS; Chin DT; Dorn PL; Herron DS; Howell KT; Kemmis TJ; Miller SA; Moore JA; Paul D
    Am J Surg; 2018 Oct; 216(4):689-693. PubMed ID: 30041733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.